Physician profile
Roger E Schultz
NPI 1417935552
$1,681.95
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $388 · 2021: $330 · 2022: $300.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $630.00 | 2021-2022 | |
| Janssen Biotech, INC. | $374.47 | 2019-2020 | |
| Astellas Pharma US INC | $343.64 | 2019-2020 | |
| Coloplast Corp | $57.35 | 2019-2020 | |
| Boston Scientific Corporation | $49.87 | 2019-2020 | |
| Olympus America INC. | $45.86 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $44.33 | 2019-2020 | |
| Allergan, INC. | $40.75 | 2019 | |
| Ferring Pharmaceuticals INC. | $30.81 | 2019-2020 | |
| Antares Pharma, INC. | $25.57 | 2020 | |
| Travere Therapeutics, INC. | $22.74 | 2019-2020 | |
| Pfizer INC. | $16.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.